semaglutide nash phase 3 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the ESSENCE Trial Phase 3 ESSENCE Trial: Semaglutide

On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing

De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, Xu D, Zimmer S, Lahrmann C, Schildberg FA, Vogelhuber J, Kraut M, Ulas T, Kerksiek A, Krebs W, Bode N, Grebe A, Fitzgerald ML, Hernandez NJ, Williams BR, Knolle P, Kneilling M, Rocken M, Lutjohann D, Wright SD, Schultze JL, Latz E

[DOI] [PubMed] [Google Scholar] 49.Bard S, Noel P, Chauvin F, Quash G

Neither peptide is FDA-approved as a standalone therapeutic, and evidence specific to perimenopausal populations remains limited